

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A method of treatment of an extracorporeal or isolated organ, comprising contacting the organ with a composition including a metal carbonyl compound or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

2. (original) A method according to claim 1 wherein the metal carbonyl makes available carbon monoxide (CO) to limit post-ischaemic damage.

3. (original) A method according to claim 1 wherein said metal carbonyl makes CO available by at least one of the following means:

- 1) CO derived by dissociation of the metal carbonyl is present in the composition in dissolved form;
- 2) on contact with a solvent the metal carbonyl releases CO;
- 3) on contact with a tissue, organ or cell the metal carbonyl releases CO;
- 4) on irradiation, the metal carbonyl releases CO.

4. (currently amended) A method according to ~~any one of claims 1 to 3~~  
claim 1 wherein said organ is extracorporeal.

5. (currently amended) A method according to ~~any one of claims 1 to 3~~ claim 1 wherein said organ is inside or attached to the body but isolated from the blood supply.

6. (currently amended) A method according to ~~any one of claims 1 to 5~~ claim 1 wherein the contacting step includes perfusing said organ with said composition.

7. (currently amended) A method according to ~~any one of claims 1 to 6~~ claim 1 wherein the metal carbonyl is a compound of the formula  $M(CO)_x A_y$  where x is at least one, y is at least one, M is a metal, the or each A is an atom or group bonded to M by an ionic, covalent or coordination bond but is not CO, and in the case where  $y > 1$  each A may be the same or different, or a pharmaceutically acceptable salt of such a compound.

8. (original) A method according to claim 7 wherein M is a transition metal.

9. (currently amended) A method according to claim 7-~~or claim 8~~, wherein A is selected from neutral or anionic ligands such as halide or derived from Lewis bases and having N, P, O, S or C as the coordinating atom.

10. (currently amended) A method according to ~~any one of claims 1 to 6~~ claim 1 wherein the metal carbonyl compound has the formula

$M(CO)_x A_y B_z$  where

M is Fe, Co or Ru,

x is at least one,

y is at least one,

z is zero or at least one,

each A is a ligand other than CO and is monodentate or polydentate with respect

to M and is selected from the amino acids

alanine

arginine

asparagine

aspartic acid

cysteine

glutamic acid

glutamine

glycine

histidine

isoleucine

leucine

lysine

methionine

phenylalanine

proline

serine

threonine

tryptophan

tyrosine

valine

$[O(CH_2COO)_2]^{2-}$  and

$[NH(CH_2COO)_2]^{2-}$ , and

B is optional and is a ligand other than CO.

11. (currently amended) ~~Use of a metal carbonyl compound in the manufacture of a medicament for treatment of an isolated organ. A method of treatment so as to limit post-ischaemic damage in an isolated organ which is inside or attached to the body but isolated from the blood supply, comprising administering a metal carbonyl to said organ.~~

Claims 12 – 15. (cancelled)